Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01365221 · ClinicalTrials.gov registry record · Phase 4

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel

A Phase 4 study of Acute Coronary Syndrome, sponsored by Medstar Health Research Institute.

Completed
Registry status
Phase 4
Development phase
77
Enrollment target
4
Study locations

NCT01365221 is a Phase 4 study of Acute Coronary Syndrome that has completed, run by Medstar Health Research Institute. The registered enrollment target is 77 participants, below the 2,720-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01365221, a Phase 4 study of Acute Coronary Syndrome, has completed, sponsored by Medstar Health Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
77 participants
Enrollment target
4
Study locations

Study Summary

The primary objective of this study is to compare platelet reactivity between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.

Conditions Studied

Interventions

  • DRUG Prasugrel

Study Locations (4)

Alabama

  • The Heart Center - Huntsville

District of Columbia

  • Washington Hospital Center - Washington D.C.

Maryland

  • Sinai Center for Thrombosis Research - Baltimore

Missouri

  • Saint Luke's Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2010-10
Est. Completion 2014-01
Phase Phase 4

Sponsor

Medstar Health Research Institute

115 total trials

What the Registry Record Tells You About NCT01365221

The ClinicalTrials.gov registry entry for NCT01365221 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,720-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (97% lower). The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Prasugrel is the first listed.

NCT01365221 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT01365221 about?

NCT01365221 is a clinical study titled "The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel". The primary objective of this study is to compare platelet reactivity between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.

What is the current status of trial NCT01365221?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2010-10. Estimated completion is 2014-01.

What conditions does trial NCT01365221 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT01365221?

The interventions under investigation include: Prasugrel (DRUG).

Who is sponsoring clinical trial NCT01365221?

This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01365221 being conducted?

This trial has 4 study locations across Alabama, District of Columbia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.